Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.

Détails

Ressource 1Télécharger: BIB_502682EFE89B.P001.pdf (1659.63 [Ko])
Etat: Public
Version: Author's accepted manuscript
ID Serval
serval:BIB_502682EFE89B
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Titre
Identification of Rare High-Avidity, Tumor-Reactive CD8+ T Cells by Monomeric TCR-Ligand Off-Rates Measurements on Living Cells.
Périodique
Cancer Research
Auteur(s)
Hebeisen M., Schmidt J., Guillaume P., Baumgaertner P., Speiser D.E., Luescher I., Rufer N.
ISSN
1538-7445 (Electronic)
ISSN-L
0008-5472
Statut éditorial
Publié
Date de publication
2015
Peer-reviewed
Oui
Volume
75
Numéro
10
Pages
1983-1991
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov'tPublication Status: ppublish
Résumé
The avidity of the T-cell receptor (TCR) for antigenic peptides presented by the peptide-MHC (pMHC) on cells is a key parameter for cell-mediated immunity. Yet a fundamental feature of most tumor antigen-specific CD8(+) T cells is that this avidity is low. In this study, we addressed the need to identify and select tumor-specific CD8(+) T cells of highest avidity, which are of the greatest interest for adoptive cell therapy in patients with cancer. To identify these rare cells, we developed a peptide-MHC multimer technology, which uses reversible Ni(2+)-nitrilotriacetic acid histidine tags (NTAmers). NTAmers are highly stable but upon imidazole addition, they decay rapidly to pMHC monomers, allowing flow-cytometric-based measurements of monomeric TCR-pMHC dissociation rates of living CD8(+) T cells on a wide avidity spectrum. We documented strong correlations between NTAmer kinetic results and those obtained by surface plasmon resonance. Using NTAmers that were deficient for CD8 binding to pMHC, we found that CD8 itself stabilized the TCR-pMHC complex, prolonging the dissociation half-life several fold. Notably, our NTAmer technology accurately predicted the function of large panels of tumor-specific T cells that were isolated prospectively from patients with cancer. Overall, our results demonstrated that NTAmers are effective tools to isolate rare high-avidity cytotoxic T cells from patients for use in adoptive therapies for cancer treatment.
Mots-clé
CD8-Positive T-Lymphocytes/immunology, Cells, Cultured, Half-Life, Humans, Kinetics, Ligands, Melanoma/immunology, Protein Binding, Receptors, Antigen, T-Cell/metabolism
Pubmed
Web of science
Open Access
Oui
Création de la notice
01/08/2015 10:01
Dernière modification de la notice
20/08/2019 15:06
Données d'usage